Green Cross’s Hunterase approved to conduct Phase 2 clinical trials in US
Green Cross’s rare disease therapies will challenge the U.S. market.
On the 12th, Green Cross(CEO Eun-cheol Huh) announced recent acquisition of approval to start Phase 2 clinical trials of ‘Hunterase(project code: GC1111),’ a Hunter’s syndrome treatment from the U.S. Food and Drug Administratio...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
